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Abstract
Background: Tuberculosis (TB) continues to be a major global health problem. While progress has been made to
improve TB cure rates, South Africa’s 76 % smear-positive pulmonary TB (PTB) case cure rate remains below the
WHO target of 85 %. We report on the trends of TB smear non-conversion and their predictors at the end of an
intensive phase of treatment, and how this impacted on treatment outcomes of smear-positive PTB cases in Eden
District, Western Cape Province, South Africa.
Methods: Routinely collected, retrospective data of smear-positive PTB cases from the electronic TB register in Eden
District between 2007 and 2013 was extracted. Non-conversion was defined as persistent sputum smear-positive PTB
cases at the end of the two or three month intensive phase of treatment. Chi-square test for linear trend and simple
linear regression analysis were used to analyse the change in percentages and slope of TB smear non-conversion rates
over time. Risk factors for TB non-conversion, and their impact on treatment outcomes, were evaluated using logistic
regression models.
Results: Of 12,742 total smear-positive PTB cases included in our study, 12.8 % (n = 1627) did not sputum smear
convert; 13.3 % (1411 of 10,574) of new cases and 9.9 % (216 of 2168) of re-treatment cases. Although not statistically
significant in either new or re-treatment cases, between 2007 and 2013, smear non-conversion decreased from 16.4
to 12.7 % (slope = −0.60; 95 % CI: −1.49 to 0.29; p = 0.142) in new cases, and from 11.3 to 10.8 % in re-treatment cases
(slope = −0.29; 95 % CI: −1.06 to 0.48; p = 0.376). Male gender, HIV co-infection and a >2+ acid fast bacilli (AFB) smear
grading at the start of TB treatment were independent risk factors for non-conversion (p < 0.001). Age was a risk factor
for non-conversion in new cases, but not for re-treatment cases. Non-conversion was also associated with unsuccessful
treatment outcomes (p < 0.01), including treatment default and treatment failure.
Conclusions: Smear-positive PTB cases, especially men and those with identified risk factors for non-conversion,
should be closely monitored throughout their treatment period. The South African TB control program should
invest in patient adherence counselling and education to mitigate TB non-conversion risk factors, and to improve
conversion and TB cure rates.
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Background
Tuberculosis (TB) remains a major public health problem
worldwide, with an estimated 9 million new cases and 1.5
million deaths reported in 2013 [1]. The latest estimates
by the World Health Organization (WHO) TB Global
Report indicates that the Asia and African regions
accounted for more than two-third of new cases in 2013,
with the highest absolute number of reported incident
TB cases in India, China, Nigeria, Pakistan, Indonesia
and South Africa [2]. Globally, South Africa ranks third
for TB burden of disease [1]. In 2010, the incidence of
TB in South Africa was 981 per 100,000 population, but
there was a gradual decline to 860 per 100,000 in 2013
due to the increased rollout of the national anti-retroviral
therapy (ART) program [2–5]. In 2013, there were
410,000–520,000 cases of TB reported in South Africa,
with more than 250,000 of these cases co-infected with
human immunodeficiency virus (HIV) [2]. While HIV has
fuelled the incidence of TB in South Africa, the emergence
of drug resistant TB is threatening to destabilize the
already constrained South African National TB Control
Program (NTCP) [6, 7].
Although considerable progress has been made in the
past decade to improve TB cure rates and treatment out-
comes, the South African TB cure rate of 76 % remains
below the WHO target of 85 % [1, 3, 8]. Furthermore,
South Africa was among the highest TB burden coun-
tries unable to achieve the highly ambitious millennium
development goals (MDG) of halving their TB prevalence
and mortality compared to the 1990 baseline, and redu-
cing the incidence of TB cases to 1 case per 1,000,000
population per year by 2015 [2]. This highlights the need
to continue strengthening the existing TB control pro-
grams to improve TB case finding, treatment outcomes
and mitigate the spread of TB infection.
In South Africa, the NTCP routinely collects TB data
in an electronic TB register (ETR.Net). ETR.Net functions
as a surveillance tool to estimate the burden of TB, guide
planning, evaluate local and national level TB control
programs and inform policy decisions on resource allo-
cation [9]. In line with WHO recommendations, the
NTCP evaluates sputum smear conversion at the end of
an intensive phase of treatment, 2 months for new cases
and 3 months for re-treatment cases [9]: smear conversion
is a strong predictor of treatment outcomes [10, 11].
Surveillance of smear conversion rates is used as an op-
erational indicator for clinical management of smear-
positive pulmonary TB (PTB) cases, effectiveness of TB
treatment and the performance of the directly observed
treatment short-course (DOTs) strategy [9]. In South
Africa, the average national rate of smear conversion
increased from 45 % in 2004 to 67 % in 2013, with the
TB cure rate for smear-positive PTB cases rising from
62 % in 2006 to 76 % in 2012 [3, 8].
In 2013, among the South Africa’s nine provinces,
KwaZulu Natal had the highest TB incidence (864 per
100,000 population), followed by Eastern Cape (792 per
100,000 population) and Western Cape (711 per 100,000
population) [8]. Of Western Cape’s six districts, Eden is
the second largest and has a TB incidence rate of 806
per 100,000 population [8]. Furthermore, Eden is the
one of ten key districts piloting the roll-out of the South
African National Health Insurance (NHI) program [8].
In support of South Africa’s efforts to achieve the global
target of 85 % TB cure rate, we undertook a retrospective
analysis of smear-positive PTB cases over a seven-year
period in Eden district. We sought to investigate the
trends and risk factors for smear non-conversion at the




A retrospective cohort of study of PTB cases was done
using routine TB programmatic data in the ETR.Net in
Eden District, Western Cape Province, South Africa, be-
tween 2007 and 2013. Only smear-positive PTB cases,
with or without extra-pulmonary TB (EPTB), with docu-
mented smear results at the end of 2- or 3-month of an
intensive phase of treatment (Fig. 1) were included. Ex-
clusion criteria were: (i) extra-pulmonary TB cases only,
(ii) smear-negative PTB cases, (iii) PTB cases with no
smear results at the start of treatment, and (iv) smear-
positive PTB cases with no smear results at the end of
2- or 3-month intensive phase of treatment.
Study setting
All cases of TB registered in the ETR.Net database in
Eden District between 2007 and 2013 were evaluated for
inclusion. Eden has an estimated population of 585,833
people and a population density of 25.1 persons per km2
[3]. With an estimated TB incidence of 806 per 100,000
population in 2013, Eden District is above the incidence
rate of 711 per 100,000 population in Western Cape
Province and 593 per 100,000 population in South Africa
[8]. Eden district is divided into seven sub-districts:
Bitou, George, Hessequa, Knysna, Kannaland, Mossel
Bay and Oudtshoorn. Eden’s TB control program is
based on a network of its sub-districts primary and
community health clinics (PHC and CHC’s), that pro-
vide TB testing, care and treatment. Treatment guide-
lines include (i) a standardized 6-month rifampicin
based regimen for new cases and an 8-month regimen
for re-treatment cases, and (ii) the evaluation of acid
fast bacilli (AFB) sputum smear conversion from posi-
tive to negative at the end of the intensive phase of
treatment: 2 months for new cases and 3 months for
re-treatment cases.
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Definitions
As per South African NTCP Practical Guidelines [9],
TB cases were defined as follows: New TB case: an
individual with a smear-positive AFB result who has
never had treatment for TB or taken anti-TB treat-
ment drugs for less than 4 weeks. Re-treatment TB
case: an individual with a smear-positive AFB result
who has taken TB treatment for 4 weeks or more in
the past and either relapsed, defaulted or had treat-
ment failure.
TB converters: PTB patient with smear-positive AFB
result prior to treatment initiation, whose AFB smear
result is negative at the end of an intensive phase of
treatment (2-month for new cases and 3-month for re-
treatment cases).
TB non-converters: PTB patient with smear-positive
AFB result prior to treatment initiation whose AFB
smear result remains positive at the end of an intensive
phase of treatment (2-month for new cases and 3-month
for re-treatment cases).
Treatment outcomes were defined according to the
South African NTCP Practical Guidelines [9] and the
2013 WHO definitions and reporting framework for
TB [12].
Successful treatment outcome: PTB cases who
completed treatment and who were declared cured.
Cured: PTB cases with completed treatment and
smear-negative AFB result at 1 month prior to the
completion of treatment and on at least one previous
occasion. Completed: PTB cases with completed treat-
ment and no AFB smear result at 1 month prior to
the completion of treatment and on at least one pre-
vious occasion.
Unsuccessful treatment outcome: PTB cases who
died, defaulted treatment, failed treatment, or were
not evaluated. Failed: PTB cases with a smear-positive
AFB result prior to treatment initiation and who
remained smear-positive at five months or later dur-
ing treatment. Died: PTB cases who died for any rea-
son during the course of treatment. Defaulted: PTB
cases whose treatment was interrupted for two or more
consecutive months. Not evaluated: PTB cases for
whom no treatment was assigned, whose treatment
outcome was unknown, or that transferred to a clinic
outside of Eden District.
Data collection
Extracted ETR.Net database variables included age,
sex, HIV status, disease classification and category,
sub-districts and clinic facilities, treatment regimen
and outcomes, and sputum smear results. Data were
exported into a Microsoft Excel spreadsheet and ana-
lysed using STATA 13.0 (Stata Corporation, College
Station, Texas, USA).
All TB cases registered in Eden District 
Municipality, 2007-2013 (n=40 033)
Pulmonary TB (PTB) cases (n=36,219)
Extra-Pulmonary TB (EPTB) 
cases only (n=3,814)
Smear-positive PTB cases (n=19,195) at 
the start of TB treatment
Smear-negative PTB cases (n=7557) 













Sputum smear at the end of intensive 
treatment phase (n=12,742)
Treatment outcome Treatment outcome
Pulmonary TB (PTB) cases 
only (n=35,382)
Both PTB and EPTB cases 
(n=837)
Fig. 1 Study flow chart showing the selection of pulmonary tuberculosis cases (n = 12,742) in the electronic TB register Eden District, Western
Cape Province, 2007–2013
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Statistical analysis
PTB cases were categorized into TB converters and
non-converters based on sputum smear results status at
the end of an intensive phase of treatment. Descriptive
statistics were used to compare baseline characteristics
of TB converters and non-converters. Continuous vari-
ables were tested for normality using Shapiro-Wilk’s W
test and expressed as mean ± standard deviation (SD)
or median and interquartile (IQR) ranges depending on
the distribution of data. Categorical variables were
expressed as frequencies (n) and percentages (%), and
analysed by the Pearson’s Chi-squared (χ2) test or two-
sided Fischer’s exact test. Chi-square test for linear
trend was used to analyse the percent change in TB
non-converters over time. Simple linear regression ana-
lysis was used to assess the percent change in the slope
of TB non-converters over time.
Univariate and multivariate logistic regressions were
used to identify predictors or factors independently asso-
ciated with TB smear non-conversion at the end of 2- or
3-month phase of intensive TB treatment, and assess
the effect of TB smear non-conversion on treatment
outcomes. A manual forward stepwise selection of the
variables with a threshold of p < 0.25 in the univariate
analysis were incorporated into a multivariate logistic
regression model to adjust for potential confounders
such as age and gender. In a logistic regression analysis,
data were expressed as unadjusted and adjusted odd ra-
tios (aOR) and 95 % confidence interval (CI). All statis-
tical tests were two-sided and a p ≤ 0.05 was considered
statistically significant.
Ethical review
Ethical clearance and approval for this study was pro-
vided by the University of Pretoria, Faculty of Health
Sciences Research Ethics Committee (Ethic Reference
no: 236/2015) and the Western Cape Provincial Depart-
ment of Health (Reference no: WC_2015RP27_678). TB
patient privacy and confidentiality were strictly main-
tained through removing personal identifying informa-
tion and allocating unique patient identifiers.
Results
Description of the study cohort
During 2007–2013, a total of 40,033 TB cases were reg-
istered in the Eden District ETR.Net database: 35,382
(88 %) PTB cases only, 837 (2 %) PTB and EPTB cases
and 3814 (10 %) EPTB cases only (Fig. 1). EPTB only
cases were excluded from our analysis. Of the 36,219
PTB cases, 19,195 (53 %) were smear-positive at the
start of TB treatment. Of these, only 12,742 (66 %) had
documented smear results at both treatment initiation
and at the end of the intensive phase of treatment
(group 1); 6453 (34 %) did not have documented smear
results at the end of the intensive phase of treatment
(group 2). Comparisons of baseline characteristics be-
tween the two groups of PTB cases revealed a signifi-
cance differences for age, gender, HIV status, and TB
classification (p < 0.0001, Table 1). No significant differ-
ences were observed between the two groups of PTB
cases in terms of disease classification (p = 0.061), pre-
treatment smear grading (p = 0.053) and sub-districts
(p = 0.887). Of the 12,742 PTB cases included in the
final analysis: mean age was 35 ± 13.1 years, 7612 (60 %)
were male and 2720 (21 %) were HIV positive (Table 1).
Of the 12,742 PTB cases included in our study, 10,574
(83 %) were classified as new cases of TB and 2168 (17 %)
were re-treatment cases.
Trends in TB sputum smear non-conversion
From 2007 to 2013, a total 1627 (12.8 %) PTB cases were
classified as TB non-converters: 13 % (1411 of 10,574) of
new cases and 9.9 % (216 of 2168) of re-treatment cases
were non-converters. The annual percent change of TB
non-conversion in new cases significantly decreased
from 16.4 % in 2007 to 12.7 % in 2013 (chi-square trend:
13.66, p < 0.001, Fig. 2a). In re-treatment cases, the an-
nual percent change of TB non-conversion decreased
from 11.4 % in 2007 to 10.8 % in 2013 (Fig. 2b), how-
ever, this decrease was not statistical significance (chi-
square trend: 1.49, p = 0.222). The percentage change in
the slope of TB non-conversion over time in a simple
linear regression revealed a non-significant decline in
new cases of TB (slope = −0.60, 95 % CI: −1.49 to 0.29,
p = 0.142, Table 2). A similar trend was observed in the
slope of TB non-conversion in re-treatment cases
(slope = −0.29, 95 % CI: −1.06 to 0.48, p = 0.376).
Of new TB cases, a statistically significant annual de-
crease in TB non-conversion was observed in Kannaland
sub-district (chi-square trend: 5.07, p = 0.0243): no sig-
nificant decrease was observed in Eden’s six other sub-
districts (see Additional file 1: Figure S1). Linear regres-
sion further revealed a statistically significant decline in
the slope of TB non-conversion in Kannaland sub-
district (Table 2, slope = −1.68, 95 % CI: −3.29 to −0.07,
p = 0.0430). In re-treatment cases, neither the decreases
in non-conversion in George, Hessequa and Mossel Bay
sub-districts, nor the increases in Knysna, Kannaland
and Oudtshoorn sub-districts were significant (see
Additional file 1: Figure S1). In Bitou sub-district, nei-
ther the decrease in non-conversion from 2007 to 2012,
nor the increase in 2013 was statistically significant.
Analysis of the changes in slope of TB non-conversion
in re-treatment cases were not significant in any of
Eden’s seven sub-districts (Table 2).
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Predictors of TB smear non-conversion
In a univariate analysis, factors found to be independ-
ently associated with TB non-conversion in new cases
were (i) age categories > 15 years, (ii) being male, (iii)
HIV infection, (iv) smear grading (> AFB+) prior to
treatment, and (v) being treated in George and Mossel
Bay sub-districts (Table 3). In contrast, new cases of
TB that received treatment between 2008 and 2013
were at a lower risk for non-conversion at the end of
2-month intensive phase of treatment than those
treated in 2007 (p < 0.01, Table 3). After adjusting for
potential confounders in a multivariate logistic regres-
sion analysis, age categories > 15 years, being male,
HIV infection and smear grading (> AFB+) remained
independently associated with non-conversion at the
end of 2-month intensive phase of treatment (Table 3).
Among re-treatment cases, risk factors for non-
conversion at the end of the 3-month intensive phase
of treatment were (i) being male, (ii) HIV infection and
(iii) smear grading (>AFB+) prior to treatment (Table 4).
Table 1 Baseline characteristics of sputum smear-positive pulmonary tuberculosis (PTB) cases in Eden District, Western Cape
Province, 2007–2013
Variables All PTB cases PTB cases with smear resultsa PTB cases without smear resultsa
n % n % n % p value
Age, years, mean (SD) 36 ± 12.8 - 35 ± 13.1 - 37 ± 12.3 p < 0.0001
Gender p < 0.0001
Female 7556 39.35 5130 40.26 2424 37.56
Male 11,641 60.65 7612 59.74 4029 62.44
HIV status p < 0.0001
Negative 13,086 68.17 9047 71.00 4039 62.59
Positive 4256 22.17 2720 21.35 1536 23.80
Unknown 1853 9.65 975 7.65 878 13.61
Disease classification p = 0.061
PTB 19,024 99.11 12,640 99.20 6384 98.93
PTB and EPTB 171 0.89 102 0.80 69 1.07
TB classification p < 0.0001
New 12,833 66.86 10,574 82.99 2259 35.01
Re-treatment 6362 33.14 2168 17.01 4194 64.99
Smear conversion statusa
Negative 11,115 87.23 11,115 87.23 - -
Positive 1627 12.77 1627 12.77 - -
Pre-treatment smear grading p = 0.053
Scanty 1670 8.70 1101 8.64 569 8.82
AFB+ 3991 20.79 2665 20.92 1326 20.55
AFB++ 3983 20.75 2659 20.87 1324 20.52
AFB+++ 8575 44.67 5712 44.83 2863 44.37
Not recorded 976 5.08 605 4.75 371 5.75
Sub-district p = 0.887
Bitou 1662 8.66 1119 8.78 543 8.41
George 7101 36.99 4731 37.13 2370 36.73
Hessequa 1245 6.49 818 6.42 427 6.62
Kannaland 940 4.90 615 4.83 325 5.04
Knysna 2088 10.88 1388 10.89 700 10.85
Mossel Bay 3090 16.10 2028 15.92 1062 16.46
Oudtshoorn 3069 15,99 2043 16.03 1026 15.90
SD Standard deviation, TB tuberculosis, AFB Acid fast bacilli, PTB Pulmonary TB, EPTB Extra-pulmonary TB
asputum smear results at the end of 2- or 3- month intensive phase of treatment
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The risk of non-conversion at the end of intensive phase
of treatment was 66 % in male and 53 % in HIV-TB co-
infected patients. In addition, re-treatment cases with
smear grades of AFB++ and AFB+++ prior to treatment
were at 3 and 5 times more likely not to smear convert at
the end of the intensive phase of treatment, respectively
(Table 4). After adjusting for potential confounders, be-
ing male, HIV infection and smear grades of AFB++ and
AFB+++ remained independently associated with smear
non-conversion at the end of the intensive phase of
treatment (Table 4).
Effects of TB smear non-conversion and treatment
outcome
Of new cases, the overall treatment success rate was
significantly lower in non-converters (78.7 %) compared
to converters (85.7 %; p < 0.0001; see Additional file 2:
Figure S2 and Table 5); unsuccessful treatment out-
come was significantly higher in non-converters (21.3
%) compared to converters (14.4 %, p < 0.0001; see
Additional file 2: Figure S2 and Table 5). A similar trend
was also observed in re-treatment cases when treatment
success and unsuccessful treatment outcomes were
Table 2 Percentage changes in the slope of TB non-conversion in Eden district, Western Cape Province, 2007-2013
Sub-districts New TB cases Re-treatment TB cases
Slope 95 % CI p value Slope 95 % CI p value
Bitou 0.17 −0.81 to 1.15 0.6717 0.61 −2.16 to 3.39 0.5941
George −0.45 −1.87 to 0.97 0.4507 −0.55 −1.72 to 0.62 0.2796
Hessequa −0.83 −1.85 to 0.21 0.0946 −0.25 −4.86 to 4.37 0.8943
Kannaland −1.68 −3.29 to −0.07 0.0430 1.94 −2.22 to 6.09 0.285
Knysna −0.70 −2.01 to 0.61 0.2261 0.19 −1.76 to 2.16 0.8069
Mossel Bay −0.73 −2.14 to 0.67 0.2393 −0.85 −1.96 to 0.26 0.106
Oudtshoorn −0.69 −0.81 to 1.15 0.6717 −0.36 −3.16 to 2.40 0.7470
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Fig. 2 Trends in tuberculosis sputum smear non-conversion rate in Eden District, Western Cape Province, 2007–2013. New (a) and Re-treatment
(b) cases TB non-converters at the end of 2- and 3-month intensive phase of treatment
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compared between converters and non-converters (see
Additional file 2: Figure S2 and Table 6).
In a univariate analysis, failure of new cases to smear
convert at 2-month was significantly associated with
“failed” (OR: 5.15, 95 % CI: 3.61–7.35, p < 0.0001),
“defaulted” (OR: 1.73, 95 % CI: 1.36–2.20, p < 0.0001) and
“not evaluated” (OR: 1.27, 95 % CI: 1.04–1.55, p < 0.0001)
treatment outcomes (Table 5). After adjusting for age,
gender, HIV and pre-treatment smear grading, this
association remained significant (Table 5). After adjust-
ing for gender, HIV status and pre-treatment smear
grading among re-treatment TB cases, non-conversion
at 3-month was significantly associated with “com-
pleted” (aOR: 1.60, 95 % CI: 1.06–2.41, p = 0.023),
“failed” (aOR: 8.14, 95 % CI: 4.25–15.57, p < 0.0001),
“defaulted” (aOR: 1.96, 95 % CI: 1.18–3.25, p = 0.009)
and “not evaluated” (aOR: 1.86, 95 % CI: 1.11–3.13, p =
0.019) treatment outcomes (Table 6).
Table 3 Predictors of tuberculosis smear non-conversion in new tuberculosis cases
Variable Total Non-converters Univariate analysis Multivariate analysis
N n % Crude OR 95 % CI p-value Adjusted OR 95 % CI p-value
Age, years 10,506 1411
0–14 157 5 3.18 Reference
15–30 4325 419 9.69 3.26 1.33–7.99 0.010 2.32 0.94–5.73 0.067
31–45 3801 596 15.68 5.65 2.31–13.8 <0.000 3.77 1.53–9.31 0.004
46–60 1816 325 17.89 6.63 2.69–16.27 <0.000 4.65 1.88–11.5 0.001
>60 407 66 16.22 5.88 2.32–14.89 <0.000 4.56 1.79–11.6 0.001
Gender 10,574 1411
Female 4380 451 10.29 Reference Reference
Male 6194 960 15.49 1.59 1.42–1.80 <0.000 1.44 1.27–1.63 <0.000
HIV 10,574 1411
Negative 7538 979 12.98 Reference Reference
Positive 2192 341 15.56 1.23 1.08–1.41 0.002 1.41 1.22–1.62 <0.000
Unknown 844 91 10.78 0.81 0.64–1.02 0.069 0.74 0.58–0.94 0.013
Pretreatment smear grading 10,574 1411
Scanty 936 47 5.02 Reference Reference
AFB+ 2271 173 7.76 1.56 1.12–2.17 0.009 1.64 1.17–2.28 0.004
AFB++ 2227 240 10.78 2.28 1.65–3.15 <0.000 2.42 1.75–3.35 <0.000
AFB+++ 4613 904 19.59 4.61 3.41–6.24 <0.000 4.83 3.56–6.55 <0.000
Not recorded 527 47 8.92 1.85 1.22–2.82 0.004 1.86 1.22–2.84 0.004
Year
2007 1461 240 16.43 Reference Reference
2008 1670 249 14.91 0.89 0.73–1.08 0.244 0.81 0.66–0.99 0.044
2009 1764 247 14.00 0.83 0.68–1.00 0.056 0.75 0.62–0.92 0.006
2010 1560 151 9.68 0.54 0.44–0.67 0.000 0.52 0.41–0.64 0.000
2011 1382 177 12.61 0.75 0.61–0.92 0.007 0.71 0.57–0.88 0.002
2012 1460 185 12.67 0.74 0.60–0.91 0.004 0.68 0.55–084 0.000
2013 1277 162 12.69 0.74 0.59–0.92 0.006 0.75 0.60–0.94 0.012
Sub-district 10,574 1411
Bitou 913 103 11.28 Reference Reference
George 3919 533 13.60 1.24 0.98–1.54 0.062 1.20 0.95–1.51 0.119
Hessequa 6.83 93 13.62 1.24 0.92–1.67 0.160 1.28 0.94–1.74 0.117
Kannaland 504 68 13.49 1.23 0.88–1.70 0.222 1.18 0.84–1.66 0.312
Knysna 1131 143 12.64 1.14 0.87–1.49 0.347 1.13 0.85–1.48 0.398
Mossel Bay 1699 241 14.18 1.29 1.01–1.66 0.037 1.28 1.00–1.66 0.050
Oudtshoorn 1725 230 13.33 1.21 0.94–1.54 0.132 1.18 0.92–1.53 0.192
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Discussion
In the present study, we report on the trends and predic-
tors of sputum smear non-conversion at the end of 2- or
3-month intensive phase of treatment and their impact
on treatment outcomes. Our analysis of 12,742 PTB
cases with documented smear results at the end of the
intensive phase of treatment, between 2007 and 2013,
showed that the overall sputum smear non-conversion
rates of new and re-treatment cases were 13.3 and 9.9 %
respectively. This translates into smear conversion rates
of 86.7 % in new cases and 90.1 % in re-treatment cases,
which is significantly higher than the South African na-
tional average of 66.7 % and NTCP’s target of 85 % for
the performance of TB control program at provincial
and district levels [3, 8, 9]. However, it is worth noting
that this data only represent one-third (35 %) of PTB
cases that were recorded in ETR.Net database. Conse-
quently, we cannot rule out that missing data in the
ETR.net database may have impacted the calculated smear
conversion rate in Eden District. This said, our findings
are comparable to prior studies conducted in Cameroon
[13] and Burkina Faso [14], and significantly lower than
those reported in Morocco [15], India [16] and Ghana
[17]. The reasons for this high smear conversion rate
observed in Eden District compared to the South African
national average rate of 66.7 % are unclear, but could be
partly explained by (i) increased funding for TB control
program [18, 19], (ii) improved access and quality of care
[20, 21] and (iii) massive anti-retroviral therapy (ART)
roll-out programme in the Western Cape Province [4, 5].
We note that there are fewer re-treatment cases in 2013
than in other years. While the exact reason for this is
unclear, incomplete data reporting and low follow-up rate
of smear results in re-treatment cases may be factors.
Additional research is needed to understand this result
and how loss to follow of smear results can be improved.
Eden District ETR.Net data reveal a non-significant
decline in the trend of smear non-conversion rates in
new and re-treatment cases of TB during the period of
2007 to 2013. This data extend and confirms the finding
of Heunis et al. [22] in Free State Province, South Africa,
who demonstrated a gradual decline in gender related
trends of 2-month smear non-conversion in new smear-
positive PTB cases from 2003 to 2009. Parallel to this
Table 4 Predictors of tuberculosis smear non-conversion in re-treatment tuberculosis cases
Variable Total Non-converters Univariate analysis Multivariate analysis
N n % Crude OR 95 % CI p-value Adjusted OR 95 % CI p-value
Gender 2168 216
Female 750 54 7.2 Reference Reference
Male 1418 162 11.42 1.66 1.21–2.29 0.002 1.68 1.21–2.33 0.002
HIV 2168 216
Negative 1509 133 8.81 Reference Reference
Positive 528 68 12.88 1.53 1.12–2.08 0.007 1.81 1.32–2.51 0.000
Unknown 131 15 11.45 1.34 0.76–2.36 0.314 1.38 0.77–2.46 0.268
Pretreatment smear grading 2168 216
Scanty 165 5 3 Reference Reference
AFB+ 394 17 4.31 1.44 0.52–3.97 0.479 1.56 0.56–4.32 0.389
AFB++ 432 38 8.79 3.08 1.19–7.98 0.020 3.54 1.36–9.20 0.009
AFB+++ 1099 152 13.83 5.14 2.07–12.7 <0.000 5.79 2.33–14.4 0.002
Not recorded 78 4 5.13 1.73 0.45–6.63 0.424 1.99* 0.52–7.68 0.315
Table 5 Effect of TB non-conversion on treatment outcome in new tuberculosis cases
Variable Non-converters Converters Univariate analysis Multivariate analysis
n % n % Crude OR 95 % CI p-value Adjusted OR 95 % CI p-value
Cured 939 66.55 6809 74.31 Reference Reference
Completed 172 12.19 1040 11.35 1.19 1.00–1.42 0.042 1.18 0.99–1.42 0.060
Died 27 1.91 129 1.41 1.51 0.99–2.31 0.052 1.33 0.86–2.05 0.205
Failed 54 3.83 76 0.83 5.15 3.61–7.35 <0.000 4.46 3.07–6.49 <0.000
Defaulted 91 6.45 380 4.15 1.73 1.36–2.20 <0.000 1.82 1.42–2.33 <0.000
Not evaluated 128 9.07 729 7.96 1.27 1.04–1.55 0.018 1.32 1.07–1.62 0.009
Mlotshwa et al. BMC Infectious Diseases  (2016) 16:365 Page 8 of 12
finding is the report by Massyn et al. [3], demonstrating
a steady increase in trends of smear conversion rates of
PTB cases in South Africa from 44 % in 2004 to 68.1 %
in 2010. Furthermore, recent data from Nanoo et al. [5]
also showed that the annual incidence of microbiologic-
ally confirmed PTB cases (per 100,000 population) in
South Africa have declined from 848 in 2008 to 774 in
2012. Of considerable interest in relation to the findings
of Nanoo et al. [5] is the observation that Western Cape
Province was the first province to show a decline in inci-
dence of confirmed PTB cases, with a 4–9 % year-on-year
decrease from 2007 until 2012. A host of TB control
programme activities, interventions and policies that were
implemented over the period of 2007–2013 in the
Western Cape Province could possibly account for the
observed decline in trends of smear-positive PTB cases
non-conversion rates in Eden District [6, 20, 23–25].
These include improved case management of TB,
multifaceted TB screening programs, introduction of
community based tracing teams, better coordination of
DOTs, integration of HIV/TB services at districts and
sub-district levels and rollout of anti-retroviral therapy
(ART) [6, 20, 23–25]. However, it was not possible to
ascribe the decline of smear non-conversion rate in Eden
District to any particular activity or intervention. Whether
this decline in trends of TB non-conversion in Eden
District is generalizable to other districts in the Western
Cape Province warrants further investigation.
Smear non-conversion at the end of 2- or 3-month
intensive phase of treatment is widely considered a poor
predictor of treatment outcome [11, 26]. Thus, under-
standing factors that affect smear non-conversion is
essential to improve TB cure rate and the success of TB
control program. Previous studies have found that age,
male gender, smoking, alcohol abuse, diabetes, high pre-
treatment smear grading, HIV status, lung cavitation, an-
aemia, previous history of TB treatment, poor quality of
anti-TB drugs, suboptimal dosage of anti-TB drugs and
presence of TB drug resistant strain to be significant
factors affecting TB smear non-conversion at the end of
intensive phase of treatment [15, 27–29]. In our study,
we identified age, high pre-treatment smear grading,
male gender and HIV infection to be independently and
significantly associated with smear non-conversion at
the end of intensive phase treatment. Our findings are
similar to those reported by Banu Rekha et al. [30] and
Caetano Mota et al. [31], which showed an association
of age, male and higher pre-treatment grading with the
lack of smear conversion at the end of intensive phase of
treatment. This is further corroborated by the retro-
spective cohort study conducted in Free State Province,
South Africa, which showed that age, pre-treatment
smear grading and TB disease classification were signifi-
cantly associated with failure to smear convert at the
end of intensive phase of treatment [32]. More recently,
Djouma et al. [33] showed that high pre-treatment smear
grading and years of treatment (2009 to 2012) were in-
dependently associated with delayed smear conversion
in a retrospective cohort study in Cameroon. In our
study, we also observed years of treatment (2008 to
2013) to be significantly associated with risk of smear
non-conversion at end of 2-month intensive phase of
treatment. We attribute this to the substantial improve-
ment in the TB control programme in South Africa
ranging from implementation of household-based case
finding [34], introduction of DOTs [35] and community-
based tracing team [23], intensified case finding [36],
provision of ART in HIV-TB co-infected patients [5],
and scaling up of Xpert MTB/RIF for early diagnosis of
TB [37, 38].
Our findings also demonstrate a dose response effect
of pre-treatment smear grading on smear non-conversion
at the end of intensive phase of treatment. Pulmonary TB
cases with baseline smear of AFB +++ in new and re-
treatment cases of TB were 5 and 6 times more likely not
to smear convert at end of intensive phase of treatment.
High bacillary load at the start of treatment could possibly
reflect the presence of lung cavitation and thus severity of
disease, which has been shown to be associated with TB
treatment failure and relapse, and the development of TB
drug resistance [39]. Moreover, there is a direct associ-
ation between the presence of lung cavitation in TB pa-
tients and high bacillary load in their sputum [39, 40]. The
lack of smear conversion at the end of an intensive phase
Table 6 Effect of TB non-conversion on treatment outcome in re-treatment tuberculosis cases
Variable Non-converters Converters Univariate analysis Multivariate analysis
n % n % Crude OR 95 % CI p-value Adjusted OR 95 % CI p-value
Cured 112 51.85 1358 69.57 Reference Reference
Completed 35 16.20 254 13.01 1.67 1.12–2.49 0.012 1.60 1.06–2.41 0.023
Died 8 3.70 53 2.72 1.83 0.85–3.94 0.123 1.73 0.78–3.80 0.174
Failed 19 8.80 28 1.43 8.23 4.45–15.19 0.000 8.14 4.25–15.57 <0.000
Defaulted 22 10.19 126 6.45 2.12 1.29–3.46 0.003 1.96 1.18–3.25 0.009
Not evaluated 20 9.26 133 6.81 1.82 1.09–3.03 0.020 1.86 1.11–3.13 0.019
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treatment with male gender has been associated with alco-
hol consumption and smoking habits [41]. However, in
our study we could not establish this association as this
data is not routinely collected in the South African
electronic TB register. Nevertheless, our findings are
consistent with several studies which have demon-
strated a significant association between male gender
and failure to smear convert at the end of the intensive
phase of treatment [15, 30, 42].
In addition to male gender, HIV infection was also
found to be significantly associated with failure to smear
convert at the end of intensive phase of treatment. This
finding is in agreement with the study of Kayigamba et
al. [43], but in contrast with studies that have reported
that HIV negative TB patients were more likely to not
smear convert at the end of intensive phase of treatment
compared to HIV positive TB patients [32] or those
whose HIV status is not known [44]. The association of
being HIV negative in the latter study was attributed to
specialist-driven treatment adherence training given to
HIV positive patients [32]. Other studies have also found
no association between HIV and lack of smear conversion
at the end of an intensive phase of treatment [13, 30, 31].
Taken together, these data raise a question on the role
of HIV status as a predictor of smear non-conversion.
Given these conflicting findings, additional studies are
needed to address the impact of HIV status on TB
smear conversion rates.
Finally, our results show that smear non-conversion at
the end of the 2- or 3-month intensive phase of treat-
ment was independently associated with the program-
matically defined outcomes of “treatment defaulter”,
“failure” and “not evaluated”. Similar findings have been
seen in studies from Cameroon [13, 27, 33], India [45]
and Nigeria [46]. These findings and our results high-
light a need for more aggressive and cost-effective strat-
egies to reduce smear non-conversion rates at the end of
intensive phase of treatment and improve TB treatment
outcomes. Our findings also highlight the need for better
surveillance and data collection on TB indicators.
Our study has several limitations. Specifically, the use
of retrospective routinely collected data in the electronic
TB register excludes the collection of other potential risk
factors. We also excluded data for which patients had
smear negative results (20.9 %), no documented smear
results at the start of the treatment (26.1 %) and end of
intensive phase of treatment (17.8 %). Furthermore, we
could not evaluate the impact of DOTs on smear con-
version rate and treatment outcomes as this data was
poorly captured in the electronic TB register database.
Finally, as South Africa maintains a separate database
for drug resistant TB cases, we could not evaluate the
impact of drug resistance on smear non-conversion
rates in this study.
Conclusions
Our main findings documents (i) a non-significant decline
in smear non-conversion trends of new and re-treatment
cases in Eden District during 2007–2013, (ii) and that
smear-positive PTB cases who are male, older than 30
years, HIV positive and have had high pre-treatment
smear grading were more likely not to smear convert at
the end of intensive phase of treatment. We also showed
that during the study period from 2008 to 2013, years of
treatment was significantly associated with lower risk of
smear non-conversion in new cases. Lastly, failure to
smear convert at the end of an intensive phase of treat-
ment was significantly associated with unsuccessful
treatment outcome in new and re-treatment cases.
Our findings highlight an urgent need in the district TB
control program to explore strategies that will mitigate
the risk of non-conversion and inform implementation of
interventions to maximize indicators for TB treatment
success rate. Targeted interventions should focus on (i)
strengthening TB treatment adherence counselling and
support, and (ii) improve follow-up of high-risk groups,
especially older men living in the communities with the
highest burden of TB and HIV. TB adherence clubs,
support groups and peer counselling for those at risk for
non-conversion may maximize patient adherence. Such
programs may be adapted from previously implemented
TB and/or HIV adherence programs [47–51]. Investing
in mobile technology systems that fast-track laboratory
test results and that reminds patients to take their TB
medication would assist the TB control activities in the
district to improve follow-up and TB indicators for
treatment outcomes. Well-designed prospective studies
are needed to formulate robust interventions. Further-
more, implementation research will inform strategies
that should be incorporated into TB control programs
to maximize TB treatment outcomes.
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